Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justus B Cohen

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Molecular Therapy. Methods & Clinical Development|July 14, 2017
Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE GenesYoshitaka Miyagawa, Gianluca Verlengia, Bonnie Reinhart, et al.
Molecular Therapy. Methods & Clinical Development|February 12, 2020
Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing AntibodiesCeren Tuzmen, Tina M Cairns, Doina Atanasiu, et al.
Virology|December 13, 2006
Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infectionMarianna Tsvitov, Arthur R Frampton, Waris A Shah, et al.
Molecular Therapy. Methods & Clinical Development|July 7, 2016
An HSV-based library screen identifies PP1α as a negative TRPV1 regulator with analgesic activity in models of painBonnie Reinhart, William F Goins, Asaff Harel, et al.
Molecular Therapy. Methods & Clinical Development|July 7, 2022
Evaluation of parameters for efficient purification and long-term storage of herpes simplex virus-based vectorsSeiji Kuroda, Yoshitaka Miyagawa, Makoto Sukegawa, et al.
Advances in Virology|August 28, 2012
Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex VirusBonnie Reinhart, Lucia Mazzacurati, Adriana Forero, et al.
Journal of Virology|October 7, 2016
Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex VirusYu Okubo, Hiroaki Uchida, Aika Wakata, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 17, 2015
Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicityYoshitaka Miyagawa, Pietro Marino, Gianluca Verlengia, et al.
Molecular Therapy Oncolytics|September 23, 2021
Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitmentJoseph W Jackson, Bonnie L Hall, Marco Marzulli, et al.
Molecular Therapy. Methods & Clinical Development|April 18, 2020
Protocol Optimization for the Production of the Non-Cytotoxic JΔNI5 HSV Vector Deficient in Expression of Immediately Early GenesSeiji Kuroda, Yoshitaka Miyagawa, Yuriko Sato, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Molecular Therapy. Methods & Clinical Development|July 14, 2017
Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE GenesYoshitaka Miyagawa, Gianluca Verlengia, Bonnie Reinhart, et al.
Molecular Therapy. Methods & Clinical Development|February 12, 2020
Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing AntibodiesCeren Tuzmen, Tina M Cairns, Doina Atanasiu, et al.
Virology|December 13, 2006
Characterization of soluble glycoprotein D-mediated herpes simplex virus type 1 infectionMarianna Tsvitov, Arthur R Frampton, Waris A Shah, et al.
Molecular Therapy. Methods & Clinical Development|July 7, 2016
An HSV-based library screen identifies PP1α as a negative TRPV1 regulator with analgesic activity in models of painBonnie Reinhart, William F Goins, Asaff Harel, et al.
Molecular Therapy. Methods & Clinical Development|July 7, 2022
Evaluation of parameters for efficient purification and long-term storage of herpes simplex virus-based vectorsSeiji Kuroda, Yoshitaka Miyagawa, Makoto Sukegawa, et al.
Advances in Virology|August 28, 2012
Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex VirusBonnie Reinhart, Lucia Mazzacurati, Adriana Forero, et al.
Journal of Virology|October 7, 2016
Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex VirusYu Okubo, Hiroaki Uchida, Aika Wakata, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 17, 2015
Herpes simplex viral-vector design for efficient transduction of nonneuronal cells without cytotoxicityYoshitaka Miyagawa, Pietro Marino, Gianluca Verlengia, et al.
Molecular Therapy Oncolytics|September 23, 2021
Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitmentJoseph W Jackson, Bonnie L Hall, Marco Marzulli, et al.
Molecular Therapy. Methods & Clinical Development|April 18, 2020
Protocol Optimization for the Production of the Non-Cytotoxic JΔNI5 HSV Vector Deficient in Expression of Immediately Early GenesSeiji Kuroda, Yoshitaka Miyagawa, Yuriko Sato, et al.
Pageof 5